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StructureHuman islet amyloid polypeptide is a hormone coexpressed with insulin by pancreatic beta-cells. For reasons
not clearly understood, hIAPP aggregates in type II diabetics to form oligomers that interfere with beta-cell
function, eventually leading to the loss of insulin production. The cellular membrane catalyzes the formation
of amyloid deposits and is a target of amyloid toxicity through disruption of the membrane's structural
integrity. Therefore, there is considerable current interest in solving the 3D structure of this peptide in a
membrane environment. NMR experiments could not be directly utilized in lipid bilayers due to the rapid
aggregation of the peptide. To overcome this difﬁculty, we have solved the structure of the naturally occurring
peptide in detergent micelles at a neutral pH. The structure has an overall kinked helix motif, with residues 7–
17 and 21–28 in a helical conformation, and with a 310 helix from Gly 33–Asn 35. In addition, the angle
between the N- and C-terminal helices is constrained to 85°. The greater helical content of human IAPP in the
amidated versus free acid form is likely to play a role in its aggregation and membrane disruptive activity.hIAPP, Human Islet Amyloid
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l rights reserved.© 2011 Elsevier B.V. All rights reserved.Human Islet Amyloid Polypeptide (hIAPP, also known as amylin)
is a 37 residue peptide hormone secreted from pancreatic β-cells
(Fig. 1). In its normal physiological role, hIAPP is associated with
appetite suppression and, in conjunction with insulin, in maintain-
ing proper glycemic levels [1]. However, a change in the cellular
environment in the early stages of type II diabetes, poorly
understood at present, causes it to aggregate into dense, insoluble
ﬁbrillar deposits that accumulate in the pancreas [2]. These
proteinaceous deposits, known as amyloid, have a characteristic
β-sheet secondary structure similar to those found in Alzheimer's,
Parkinson's, Huntington's, and a variety of other degenerative
disorders [3]. Like the amyloid deposits found in these diseases,
hIAPP aggregates of various forms have been linked to cellular death
and impairment of normal tissue functioning [4,5].
One of the primarymechanisms by which hIAPP and amyloidogenic
peptides in general cause cellular death is the disruption of the integrity
of the cellular membrane [6]. Human islet amyloid polypeptide, but notthe non-amyloidogenic rat variant, has been shown to cause signiﬁcant
impairment of the integrity of the phospholipid membrane in both
model membranes and in cells [7–12]. The exact mechanism of
membrane disruption is unknown but has been linked to peptide
aggregation on the membrane surface [7,10,11]. Binding of hIAPP to
lipid membranes also markedly accelerates the aggregation to ﬁbril
formation, a factor that is likely to be important in determining the ﬁnal
amount of amyloid deposition [13–15].
Structural studies report that monomeric hIAPP is primarily, but
not completely, unstructured before it aggregates to form β-sheet
ﬁbers [16–18]. While a structural model for hIAPP amyloid-ﬁbers has
been created from solid state NMR measurements [19], solving the
high-resolution structure of hIAPP in a membrane environment has
been a major challenge due to the rapid aggregation of hIAPP in the
presence of membranes [13]. Low-resolution structural studies have
shown that human-IAPP initially binds to the membrane in a helical
state [20–23], and a recent NMR study reported the structure of the
free-acid form of hIAPP at a low pH in SDS micelles [24]. Once bound
to the membrane, aggregation of the peptide causes a cooperative
conformational change from the helical conformation to the β-sheet
amyloid form [20,21,23,25].
While these studies have provided evidence for a helical
conformation of the peptide, the high-resolution 3D structure of the
membrane-associated hIAPP peptide in its natural form at physiolog-
ical pH has not been reported. In this study, we have solved the high-
resolution structure of C-terminus-amidated hIAPP (similar to in the
Fig. 1. Primary sequence of human-IAPP including the disulﬁde bridge between Cys2–
Cys7 and amidated C-terminus.
Fig. 2. Alpha-proton chemical shift index for hIAPP embedded in SDS micelles. The CSI
was calculated by subtracting the appropriate random coil chemical shifts reported in
the literature. A CSI≤−0.1 is considered indicative of a helical conformation.
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topology with respect to the micelle at physiological pH. Our results
indicate a substantial structural difference in the C-terminus of the
peptide between the two versions of the peptide, which is disordered
in the previous hIAPP NMR structure but is ordered under the
conditions employed in this study, which likely has implications for
the mechanism of membrane-mediated aggregation and membrane
disruption by hIAPP.
1. Materials and methods
1.1. Sample preparation
Human-IAPP (hIAPP) was synthesized and puriﬁed by SynBioSci
(Toronto, ON) with a disulﬁde bridge from residues Cys 2–Cys 7 and
an amidated C-terminus. The peptide was dissolved in hexaﬂuor-
oisopropanol to monomerize the preformed aggregates of hIAPP, and
then lyophilized to remove the solvent. For NMR experiments, the
sample was prepared by dissolving a 3 mg of lyophilized peptide in
20 mM sodium phosphate buffer at pH~7.3 containing 10% D2O,
120 mM NaCl and 200 mM perdeuterated SDS (Cambridge Isotopes
Laboratory) to a ﬁnal peptide concentration of 2.5 mM.
1.2. NMR data collection and processing
All NMR experiments on SDS micelles containing hIAPP were
performed at 25 °C using a 900 MHz Bruker Avance NMR spectrom-
eter equipped with a triple-resonance cryogenic probe. After
optimizing the experimental parameters using 1D 1H NMR spectrum
of the sample, a 2D 1H–1H TOCSY spectrum was recorded with an
80 ms mixing time and 2D 1H–1H NOESY spectra were recorded at
100 ms and 300 ms mixing times in order to assign backbone and
side-chain resonances. Complex data points were acquired for
quadrature detection in both frequency dimensions of the 2D
experiments. For all the spectra, zero-ﬁlling was performed in both
dimensions to yield matrices of 2048×2048 points. Proton chemical
shifts were referenced by setting the water peak at 4.7 ppm, as DSS
has been found to bind some amyloidogenic proteins and may affect
the conformation [26]. All 2D spectra were processed using TopSpin
2.1 software (from Bruker) and analyzed using SPARKY [27].
Resonance assignments were done using a standard approach as
reported elsewhere [28].
1.3. Structure calculations
The ﬁnal structure calculations were carried out with the CYANA
2.1 program package using simulated annealing in combination with
molecular dynamics in torsion angle space [29]. NOE connectivities
were used for the calculation of dihedral angle restraints [30].
Unambiguous long-range NOE constraints were used during the ﬁrst
round of structure calculations to generate an initial low-resolution
structure. The remaining ambiguous NOE cross-peaks were assigned
in an iterative fashion by applying a structure-aided ﬁltering strategy
in repeated rounds of structure calculations [31]. A total of 500
conformers were calculated using 8000 annealing steps for each
conformer after complete assignment of resonances. The lowest 20
energy conformers were selected and visualized using MOLMOL [32].
The values of Wishart et al. were used for the random coil chemical
shifts [33].1.4. Paramagnetic quenching
2D 1H–1H TOCSY spectra of hIAPP embedded in SDS micelles were
recorded in the absence and in the presence of 0.8 mMMnCl2. All the
other experimental conditions were the same as mentioned above.
2. Results
2.1. 3D structure of hIAPP in SDS micelles
2D 1H–1H TOCSY and NOESY spectra of hIAPP embedded in SDS
micelles were used to assign the backbone and side chain resonances
of the peptide. The deviation of the Hα chemical shifts from the
corresponding values for a random coil structure (Hα chemical shift
index) was used as an indicator of the secondary structure of the
peptide. In an α-helical structure, Hα protons experience a shift to
higher ﬁeld corresponding to a negative deviation in the CSI plot. A
negative deviation spanning 3 or more residues indicates the
propensity for an α-helical conformation. The CSI plot shows the
propensity for a helix formation in two regions of the hIAPP, a longer
helix in the region Ala 5–Ser 28 and a shorter helix from Ser 34 to Tyr
37 as shown in Fig. 2. The chemical shift value for the Hα proton of Cys
2 was not observed in the spectra, most likely due to a chemical
exchange process.
The ﬁngerprint region of the NOESY spectra obtained at a 300 ms
mixing time is shown in Fig. 3 with sequential assignment of
residues. From the analysis of 2D NOESY spectra, we have assigned a
total of 568 (446 short, 119 medium and 3 long range) NOEs for
hIAPP (Fig. 4). The ﬁnal 3D structure of the peptide is presented in
Fig. 5 (PDB id 2L86). The superposition of backbone atoms from
residues 7 to 37 gives an RMSD of 0.46±0.15 Å as shown in Fig. 5,
while the superposition of all heavy atoms gives an RMSD of 1.09
±0.23 Å (see Table 1 for more structure statistics). Three helical
domains are evident from the numerous dNN(i,i+1), dNN(i,i+2),
dαβ(i,i+3), dαN(i,i+3) and dαN (i,i+4) NOE connectivities that are
diagnostic of an α-helix as shown in Fig. 5. Two of the helical
domains extending from residues Cys 7–Val 17 and Asn 21–Ser 28
are α-helices, while the third is a short 310-helix extending from Gly
33 to Asn 35. The twoα-helices are separated by a turn from residues
His 18–Ser 20. The break in the N-terminal α-helix at His 18, also
present in the previous NMR structure of the recombinant hIAPP
[24], is conﬁrmed by the absence of dαβ(i,i+3), dαN(i,i+3) NOEs
from Leu 16–Ser 19 and His 18–Ser 20 that would be present if Leu
16–Ser 19 were in a helical conformation (Fig. 4). Unlike the
Fig. 3. The ﬁngerprint region of 2D 1H–1H NOESY spectrum of hIAPP in SDS micelles showing sequential Hα–HN NOE connectivities.
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freely about the ﬁrst helix but is constrained in a bent conformation
with an inter-helical angle determined by MOLMOL to be 85°±5°.
This constraint between the two helices can be attributed to the
presence of dαN(i,i+2) and dαN(i,i+3) NOEs from V17 to S19 and
V17 to S20 which limit the conformational space to the bent
conformation observed in the structure (Fig. 4).
The 310-helix from Gly 33 to Asn 35 found in this study was not
observed in the structure of the recombinant hIAPP. The absence of
dNN(i,i+3), dαβ(i,i+3), and dαN (i,i+4) NOEs in the spectra of
recombinant hIAPP in this region [24], as well as their presence in the
current study, support this difference between the two structures. In
particular, dNN(i,i+3) NOEs from Val32–Asn35 and Gly 33–Thr 36, a
dαβ(i,i+3) NOE from Val 32–Asn 35, and a dαN (i,i+4) NOE from
Thr30–Ser 34 (Fig. 4) indicate the existence of a helical conformation
from Gly 33 to Asn 35, none of which were observed in the spectra of
recombinant hIAPP [24]. The presence of dαN(i,i+2) NOEs spanning
Thr 30-Val 32, Gly 33-Asn 35, and Ser 34–Thr 36 indicates the
formation of a 310-, rather than α-, helix (Fig. 4). This contention is
further supported by the observation of a hydrogen bonds in the ﬁnal
structure between the backbone of Gly 33 to Thr 36 and Ser 34 and the
C-terminal amide, an i to to i+3 pattern typical for 310 helices.
2.2. Localization of hIAPP in SDS micelles
In order to ﬁnd the orientation of the peptide with respect to the
SDS micelle, we have performed paramagnetic quenching experi-
ments using MnCl2 as a paramagnetic ion. Since Mn2+ ions are less
likely to penetrate into the hydrophobic interior of the micelle, only
residues exposed to solvent experience the paramagnetic induced
relaxation effect that results in broadening of the correspondingFig. 4. A summary of the sequential and medium range NOE connectivities for hIAPP in
SDS micelles. The intensities of the observed NOEs are represented by the thickness of
lines and are classiﬁed as strong, medium, and weak.peaks. In the 2D TOCSY spectrum recorded in the presence of 0.8 mM
MnCl2, most of the resonances in the ﬁnger print region disappeared
as shown in Fig. 6, indicating most of the residues of hIAPP are
exposed to the solvent and the peptide is located close to the surface
of the micelle. However, the Hα protons of T9, R11 and L12, the side
chain peaks of K1, N3, Q10, R11, N14, and the amide protons of C2,
A5–A13, F15, L16, S20, A25, S29, V32, T36 and Y37 are still observable
but with a reduced intensity. These results indicate that the side
chains of residues in theα-helical region Cys 7–Val 17, as well as some
of the residues in the C-terminus, are most likely embedded into the
head group region of the detergent.
3. Discussion
The misfolding and aggregation of hIAPP and related structural
changes depends on a variety of experimental conditions such as pH,
ionic concentration, peptide concentration and temperature in
solution. Several biophysical studies have reported the structural
changes accompanying the changes during aggregation in solution
from the random coil monomeric peptide to the β-sheet amyloid
aggregate [34–41]. The interaction of the peptide with the lipid
membrane is of signiﬁcant interest as it increases the rate of peptide
aggregation which can in turn result in membrane disruption [13,23].
While solving the high-resolution structure of the peptide in aFig. 5. High-resolution NMR structures of hIAPP in SDS micelles at physiological pH.
Note that the N-terminal helix from C7–V17 is separated from the other helix from
N21–S28 by a turn comprising of residues H18–S20 and the C-terminus has a short
310-helix comprising of residues G33–N35.
Table 1
Statistical information for the hIAPP structural ensemble.
Distance constraints
Total 568
Short (i− j≤1) 446
Medium (i− j=2, 3, 4) 119
Long (i− j≥5) 3
Structural statistics
Violated distance constraints 0
Violated angle constraints 0
RMSD of all backbone atoms (Å) (Cys 7–Tyr 37) 0.49±0.17
RMSD of all heavy atoms (Å) (Cys 7–Tyr 37) 1.32±0.27
Ramachandran plot
Residues in most favored region (%) 86.6
Residues in additionally allowed region (%) 10.8
Residues in generously allowed region (%) 2.6
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has been difﬁcult to apply NMR techniques in lipid vesicles due to the
fast aggregating nature of the sample. To overcome this limitation, in
this study we have utilized SDS micelles to stabilize the intermediate
structure of hIAPP at pH 7.3 and solved the 3D structure and its
membrane orientation.
As shown in Fig. 5, our studies reveal that the structure of
amidated hIAPP in SDS has an overall kinked helix motif, with
residues 7–17 and 21–28 in a helical conformation, and with a 310
helix from Gly 33–Asn 35. In addition, the angle between the N- and
C-terminal helices is constrained to 85°. The helix-turn-helix structure
of hIAPP is a common motif found in many of the high-resolution
structures of amyloids bound to the detergent micelles, where an
amphipathic helix is separated from a more polar helix by a short
ﬂexible region. In all these high-resolution structures there is aFig. 6. 2D 1H–1H TOCSY spectra of hIAPP in SDS micelles at physiological pH in the
absence (top) and presence (bottom) of 0.8 mM MnCl2.variable degree of conformational ﬂexibility, as the location of the
linker as well as length of the helical regions vary depending upon the
experimental conditions [24,42–45]. The location of the kinks in the
structure in detergent micelles for amyloidogenic peptides largely
correlates with the location of the turns in the structure of the amyloid
ﬁber [19,46–49].
The overall structure of hIAPP without amidation in the C-terminal
obtained at pH 4.6 [21] resembles the structure presented here of the
naturally-occurring C-terminal amidated form of hIAPP obtained at
neutral pH as compared in Fig. 7. However, two important differences
exist between the conditions used to solve the structure of the free
acid form of IAPP at an acidic pH and those likely to be encountered by
hIAPP in the physiological setting. First, since pH plays an important
role in the membrane binding properties of hIAPP, the structure and
membrane orientation obtained at an acidic pH of 4.6 may not be
physiologically relevant. For example, a recent NMR study on a
truncated version of hIAPP (hIAPP1–19) showed that protonation of
His 18 causes a change in its membrane binding topology from a
buried to a surface associated state [50]. This observed change in
membrane topology with pH was linked with a greatly reduced
potential of hIAPP1–19 to disrupt phospholipid vesicles, a phenomenon
that was also observed for β-cell membranes as demonstrated by a
H18R hIAPP1–19 mutant [8]. Further, the aggregation of hIAPP is
strongly pH dependent [34,51], with protonation of H18 slowing the
aggregation by a factor of ~4 [51]. The decrease in the aggregation
potential of hIAPP at acidic pHs is one factor that allows hIAPP to be
safely stored in the secretory granule (pH ~5.5) in a presumably non-
aggregated form [52].
Second, hIAPP is normally expressed with an amidated C-terminus
that is essential for proper biological function [53]. The NMR study
used a recombinant form of the peptide with a non-amidated C-
terminus, altering the electrostatic interactions at the C-terminal end
of the peptide [24]. This small change is signiﬁcant for hIAPP as studies
have shown that the free acid of hIAPP is signiﬁcantly less
amyloidogenic than the amidated version [17]. In addition, a recent
study has shown relatively strong interactions between protonated
His 18 and Tyr 37 [40], which may partly be attributable to a salt
bridge formation between His 18 and the C-terminus, an interaction
that will not occur in the amidated peptide. Since environmentalFig. 7. Overlay of the ensemble of NMR structures of hIAPP in SDS micelles solved at
acidic pH (blue) and physiological pH (red). Note that the N-terminal helix (residues to
7 to 17) overlays quite well, while a substantial deviation is observed for the second
helix from 21 to 28.
Fig. 8. A possible schematic model for the aggregation of hIAPP in the presence of lipid
membranes. (A) hIAPP initially binds to the membrane in a helical conformation.
(B) Once bound to the membrane, hIAPP aggregates on the membrane surface to form
helical bundles (C) Aggregation of the peptide causes a conformational change in the
less structured C-terminus to the β-sheet conformation of the amyloid form.
(D) Formation of β-sheets at the C-terminus triggers a corresponding conformational
change at the N-terminus, producing the ﬁnal amyloid ﬁber.
2341R.P.R. Nanga et al. / Biochimica et Biophysica Acta 1808 (2011) 2337–2342conditions can have a strong impact on the structure and membrane
perturbing activity of the peptide, it is important to determine the
structure of membrane-bound hIAPP under conditions more close to
the physiological state.
Although the overall helix-turn-helix motif of the previous
structure is preserved (see Fig. 7), the kink is much more pronounced
in the new structure of hIAPP determined in this study. While the N-
terminal α-helix of both the structures overlays well from Cys 7–Val
17 with a backbone RMSD of 0.48±0.25 Å as shown in Fig. 7, the
second helix deviates signiﬁcantly from each other. At acidic pH, the
helix from Asn 22–Ser 28 in the hIAPP free acid wobbles about the N-
terminal helix with an inter-helical angle of 30 °C [24]. By contrast, the
Asn21–Ser28 helix of C-amidated-hIAPP at neutral pH is constrained
to lie at an interhelical angle of 85°. The strongly bent aspect of the
structure resembles those of hIAPP and the related pramlintide
construct determined at neutral pH in ﬂuorinated organic solvents
[51,54], suggesting the kink in the helix is not enforced by membrane
binding. In both structures the region of the peptide constrained by
the disulﬁde ring is partially unstructured and pointing away from the
hydrophobic side of the N-terminal helix [24].
In addition to the differences observed in the kink region of the
peptide, a substantial difference exists at the C-terminal end. In our
structure residues Gly33 to Asn35 at the C-terminal end of the peptide
are in a 310 helical conformation, in comparison to the conformation-
ally unconstrained C-terminus found in the structure of Patil et al.
[24]. The CD spectra of hIAPP at pH 4.6 and 10.8 are similar, suggesting
that the change in the protonation state of His18 is not responsible for
the observed differences [24]. The formation of the 310 helix from
Gly33 to Asn35 is therefore most likely due to the change from an
unprotected, negatively charged C-terminus to the amidated, un-
charged variant present in the physiologically expressed peptide. The
negatively charged free acid will unfavorably interact with the
headgroup of SDS and negatively charged lipids, while the amidated
version not only lacks this unfavorable interaction but also has the
potential for favorable hydrogen bonding interactions with the
detergent or lipid headgroup.
Several lines of evidence point to the importance of the C-terminal
end of hIAPP in amyloid formation. First, as a peptide fragment,
residues 30–37 independently form amyloid deposits [55]. Second,
mutations at the C-terminal can adversely affect the kinetics of
amyloid formation. For instance, mutations of Asn31 to Leu or Asn35
to Leu are sufﬁcient for a three-fold decrease in the ﬁbrillogenesis rate
[56], while mutations of Asn31 to Ser or Val32 to Ala abolish amyloid
formation [57]. Third, the hIAPP free acid aggregates signiﬁcantly
slower (1/9 the rate) than the amidated variant, suggesting
electrostatics at the C-terminal end plays a key role in aggregation
[17]. Fourth, the entire C-terminus is incorporated into the amyloid
ﬁber in the current structural model of hIAPP amyloid ﬁbers,
indicating interactions of the C-terminal with the N-terminal stabilize
the ﬁnal structure [19]. Finally, the N-terminal regions of hIAPP and
the nonamyloidogenic and nontoxic rat-IAPP variant are similar, with
most of the differences in structure concentrated at the C-terminal
end [50,58]. Taken together, these ﬁndings raise the possibility that,
while the C-terminus is not strictly essential for amyloid formation by
hIAPP [59], its conformation can signiﬁcantly modulate the kinetics of
amyloid formation (see Fig. 8 for a possible model).
The existence of a structuredC-terminus is signiﬁcant for a structural
interpretation of bothmembrane-mediated andmembrane-free aggre-
gation of hIAPP. The transition from a conformationally unconstrained
monomeric peptide to the highly ordered amyloid supermolecular
complex is entropically disfavored. For this reason, amyloid formation
from conformationally unconstrained monomers is frequently kineti-
cally inaccessible, despite the overall favorable free energy change
associated with amyloid formation for hydrophobic sequences [60].
Partially structured intermediates can reduce the entropic cost of the
highly disfavored initial step of amyloid formation by favorablypositioning aggregation prone regions to interact with each other. In
particular, there is evidence for a mechanistic role for helical in-
termediates in amyloid aggregation [3,61]. Helical intermediates have
been directly observed for some amyloidogenic proteins and have been
indirectly inferred for others from mutational analysis and solvent
perturbation studies [62,63]. Inhibitors have been constructed that
utilize this fact to stop amyloid formation by either excessively
destabilizing or overstabilizing the helical state [64,65]. 310 helices are
particularly suited for undergoing a helix to beta sheet transition due to
the relative similarities in the phi/psi torsion angles between the beta-
sheet and 310 helix conformations and the relative ease of partially
unfolding a 310 helix compared to the α-helix conformation [3].
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